Jorgensen, R. Scott, B. Korczak; PolyMedix, Inc., Radnor, PA. L1-1663 Fang De Anda Montalto

163 TUESDAY SCIENTIFIC SESSIONS Final Program ------------------------------------------------------------------------ 189 L1 Poster Session Novel Agents and Insights in Skin and Soft Tissue Infections Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: L1-1659 Initial Analysis of the CAPTURE Study: Ceftaroline Fosamil for the Treatment of Acute Bacterial Skin and Skin Structure Infections ABSSSI Including Special Risk Groups

P. Santos

1 , A. Davis 2 , A. Jandourek 3 , Y. Li 3 , H. Friedland 3 ; 1 Lakes Region Gen. Healthcare, Laconia, NH, 2 Provena United Samaritans Med. Ctr., Danville, IL, 3 Cerexa, Inc., Oakland, CA. L1-1660 Microbiological Activity and Outcome of the Pleuromutilin BC-3781 in a Clinical Phase 2 Trial in Acute Bacterial Skin and Skin Structure Infections ABSSSI

S. Paukner

1 , Z. Ivezic-Schoenfeld 1 , K. J. Tack 2 , D. F. Sahm 3 , W. T. Prince 1 ; 1 Nabriva Therapeutics AG, Vienna, Austria, 2 n.a., Brighton, MI, 3 Eurofins Medinet Ltd, Chantilly, VA. L1-1661 Safety Among Hospitalized Patients Receiving Ceftaroline Fosamil CPT-F Treatment: A USA Retrospective Analysis of a Large Hospital Claims Database Using ICD-9-CM Codes

X. Huang, B.Pharm

1 , A. Jandourek 2 , S. Laussucq 2 ; 1 Forest Res. Inst., Inc., Jersey City, NJ, 2 Cerexa, Inc, Oakland, CA. L1-1662 A Phase 2 Randomized, Double-Blinded, Dose-Ranging, Active Controlled Efficacy and Safety Evaluation of PMX-30063 for the Treatment of Acute Skin Skin Structure Infections ABSSSI Caused by Staphylococcus aureus SA

D. Jorgensen, R. Scott, B. Korczak; PolyMedix, Inc., Radnor, PA. L1-1663

Results of a Phase 2 Study of Delafloxacin DLX Compared to Vancomycin VAN and Linezolid LNZ in Acute Bacterial Skin and Skin Structure Infections ABSSSI

L. E. Lawrence

1 , J. Longcor 1 , S. Hopkins 1 , S. Green 2 , P. Mehra 2 , W. Sears 2 , W. D. O’Riordan 2 , P. Manos 2 ; 1 Rib-X Pharmaceuticals Inc., New Haven, CT, 2 eStudySite, San Diego, CA. L1-1664 Safety Profile of Tedizolid Phosphate Compared to Line- zolid in a Phase 3 ABSSSI Study

E. Fang

1 , C. De Anda 1 , A. Das 2 , P. Prokocimer 1 ; 1 Trius Therapeutics, San Diego, CA, 2 Axistat, San Francisco, CA. L1-1665 Comparison of Investigator Assessed Clinical Outcome Over Time of Tedizolid Phosphate vs Linezolid in a Phase 3 Study in Patients with ABSSSI

C. De Anda

1 , E. Fang 1 , S. Green 2 , P. Mehra 3 , P. Prokocimer 1 ; 1 Trius Therapeutics, San Diego, CA, 2 eStudySite, La Mesa, CA, 3 eStudySite, Chula Vista, CA. L1-1666 Inter-Country Differences in Microbiological Testing and Diagnoses for cSSTI in Hospitalized Patients: Results from the European REACH Study J. Garau 1 , F. Blasi 2 , J. Medina 3 , M. Ávila 4 , K. McBride 5 , H. Ostermann 6 ; 1 Hosp. Univ. Mutua de Terrassa, Barcelona, Spain, 2 Univ. Degli Studi di Milano, Milan, Italy, 3 AstraZeneca, Madrid, Spain, 4 AstraZeneca Europe, Zaventem, Belgium, 5 Instat Services, Inc., Chatham, NJ, 6 Univ. Hosp. Munich, Munich, Germany. L1-1667 Skin Surface Temperature: An Objective Measure of Severity and Treatment Response in Acute Skin and Soft Tissue Infection

M. Montalto

1,2 , F. Davies 2 , N. Marijanovic 2 , A. Meads 3 ; 1 Epworth Hosp., Richmond, Australia, 2 Royal Melbourne Hosp., Parkville, Australia, 3 Pegasus Health, Christchurch, New Zealand. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 190 M Poster Session Clinical Mycology I Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: M-1668 A Built-in Multiplex Protocol to Identify the Opportunistic Fungal Pathogen Candida glabrata A. De Las Peñas, D. Barron, M. Cuellar, I. Castaño; Inst. Potosino de Inves- tigacion Cientifica y Tecnologica, San Luis Potosi, San Luis Potosi, Mexico. M-1669 Clinical Characteristics of Candidemia in Adults with Hematological Malignancy and Antimicrobial Susceptibilities of the Isolates at a Medical Center in Taiwan, 2001-2010

H. Y. Tsai